|Bid||2.0400 x 0|
|Ask||2.0400 x 0|
|Day's Range||2.0200 - 2.1200|
|52 Week Range||1.4800 - 4.4900|
|Beta (5Y Monthly)||1.74|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.71|
Subscribe to Yahoo Finance Plus to view Fair Value for ONC.TO
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab...
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript November 3, 2023 Oncolytics Biotech Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07. Operator: Good morning, and welcome to Oncolytics Biotech’s Third Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the […]